317 related articles for article (PubMed ID: 31570469)
21. [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].
Watanabe T; Koyama N
Nihon Yakurigaku Zasshi; 2019; 153(5):242-248. PubMed ID: 31092758
[TBL] [Abstract][Full Text] [Related]
22. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
23. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.
Zhao Y; Zhang YN; Wang KT; Chen L
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188391. PubMed ID: 32659252
[TBL] [Abstract][Full Text] [Related]
24. Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated.
Li S; Li Y
Hepatol Int; 2024 Apr; 18(2):704-705. PubMed ID: 37943415
[No Abstract] [Full Text] [Related]
25. Lenvatinib mesylate to treat hepatocellular carcinoma.
Ielasi L; Tovoli F; Piscaglia F
Drugs Today (Barc); 2019 May; 55(5):305-313. PubMed ID: 31131841
[TBL] [Abstract][Full Text] [Related]
26. AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
Altayar O; Shah R; Chang CY; Falck-Ytter Y; Muir AJ
Gastroenterology; 2022 Mar; 162(3):937-951. PubMed ID: 35210015
[No Abstract] [Full Text] [Related]
27. The Outcome of Conversion Liver Resection Surgery by Lenvatinib Treatment: A Single Center Experience.
Hidaka M; Hara T; Soyama A; Sasaki R; Matsushima H; Tanaka T; Hamada T; Imamura H; Adachi T; Kanetaka K; Miyaaki H; Okano S; Eguchi S
Anticancer Res; 2022 Jun; 42(6):3049-3054. PubMed ID: 35641262
[TBL] [Abstract][Full Text] [Related]
28. Surgical Intervention After Lenvatinib Treatment in Patients With Advanced Hepatocellular Carcinoma.
Okuno M; Hatano E; Tada M; Nishimura T; Okamoto T; Sueoka H; Iida K; Nakamura I; Iijima H; Hirono S
Anticancer Res; 2024 Apr; 44(4):1727-1737. PubMed ID: 38537993
[TBL] [Abstract][Full Text] [Related]
29. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
Nakamura K; Beppu T; Hayashi H; Okabe H; Imai K; Nitta H; Chikamoto A; Ishiko T; Sasaki M; Baba H
Int Surg; 2015 May; 100(5):908-14. PubMed ID: 26011214
[TBL] [Abstract][Full Text] [Related]
30. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
[TBL] [Abstract][Full Text] [Related]
31. Balloon-Assisted Chemoembolization Using a Micro-Balloon Catheter Alongside a Microcatheter for a Hepatocellular Carcinoma with a Prominent Arterioportal Shunt: A Case Report.
Hoshiai S; Mori K; Ishiguro T; Konishi T; Uchikawa Y; Fukuda K; Minami M
Cardiovasc Intervent Radiol; 2017 Apr; 40(4):625-628. PubMed ID: 27987001
[TBL] [Abstract][Full Text] [Related]
32. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Oikonomopoulos G; Aravind P; Sarker D
Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
[TBL] [Abstract][Full Text] [Related]
33. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
34. Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
Honda S; Saito Y; Sawada K; Hasebe T; Nakajima S; Okumura T
Intern Med; 2020 Mar; 59(5):657-662. PubMed ID: 31735795
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
[TBL] [Abstract][Full Text] [Related]
36. Lenvatinib-induced acute acalculous cholecystitis in a patient with hepatocellular carcinoma.
Ishigaki K; Hamada T; Nakai Y; Ishigaki Y; Oyama H; Kanai S; Suzuki T; Nakamura T; Sato T; Hakuta R; Saito K; Saito T; Takahara N; Mizuno S; Kogure H; Tateishi R; Tada M; Koike K
Clin J Gastroenterol; 2020 Aug; 13(4):568-571. PubMed ID: 32242306
[TBL] [Abstract][Full Text] [Related]
37. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Hagymási K; Tulassay Z
Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
[TBL] [Abstract][Full Text] [Related]
38. The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
Yoshimoto T; Imura S; Morine Y; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Takasu C; Ishikawa D; Teraoku H; Bando Y; Shimada M
Anticancer Res; 2018 Jan; 38(1):501-507. PubMed ID: 29277815
[TBL] [Abstract][Full Text] [Related]
39. Double-Balloon-Assisted n-Butyl-2-Cyanoacrylate Embolization of Intrahepatic Arterioportal Shunt Prior to Chemoembolization of Hepatocellular Carcinoma.
Takao H; Shibata E; Ohtomo K
Cardiovasc Intervent Radiol; 2016 Oct; 39(10):1479-83. PubMed ID: 27224984
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant combined strategy to surgery based on chemoembolization and lenvatinib in hepatocellular carcinoma.
Colón Rodríguez A; Velasco Sánchez E; Rodríguez-Bachiller L; Díaz-Zorita B; López Baena JÁ; Álvarez Luque A; Rincón Rodríguez D; Matilla Peña AM
Gastroenterol Hepatol; 2022; 45(6):490-491. PubMed ID: 34400190
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]